Clinical trials sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase breakdown

Conditions studied

Recruiting trials led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences

• A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer
  NCT07026669 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma
  NCT07063888 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• A Prospective Study of Preoperative Tumor-bed Boost Followed by Oncoplastic Surgery and Adjuvant Whole Breast Radiotherapy for Early Stage Breast Cancer (BIRKIN)
  NCT05603078 · Phase: Not applicable (e.g. observational or device study) · Ages: Up to 55 Years · Sex: Female · 1 location
• A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer
  NCT06776861 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis.
  NCT06839547 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Retrospective Real-World Study Based on RATIONALE-307
  NCT07478809 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma
  NCT07557251 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Adaptive Radiotherapy for Genitourinary Cancers
  NCT07324798 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · 1 location
• Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer
  NCT06789679 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• An Exploratory Clinical Study Evaluating the Safety and Efficacy of Allogeneic CAR-NK Cell Therapy for Metastatic Castration-resistant Prostate Cancer (mCRPC)
  NCT07298239 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
  NCT07443397 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
  NCT05761366 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
  NCT06255197 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
  NCT05983107 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
  NCT07166003 · Phase: Not specified · Ages: 18 Years to 79 Years · Sex: All (male and female) · 1 location
• Establishment of a Multi-omics Prediction Model for Early Triple-negative Breast Cancer Based on UPGRADE-TNBC Study
  NCT07773818 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
  NCT05188859 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC
  NCT07724223 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors.
  NCT06928922 · Phase: Early Phase 1 · Ages: Up to 99 Years · Sex: All (male and female) · 1 location
• Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
  NCT06202001 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases
  NCT06848842 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
  NCT05886439 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)
  NCT05183074 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · 1 location
• NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
  NCT06405490 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer
  NCT06405139 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer
  NCT07352280 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
  NCT06897046 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Prospective Validation and Application of an Artificial Intelligence-based Model for Evaluating the Efficacy of Breast Cancer Patients After Neoadjuvant Therapy
  NCT06649565 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · 2 locations
• Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery
  NCT06483698 · Phase: Not specified · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
  NCT06993506 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 19 locations
• Response-Based Local Therapy for Regionally Advanced Breast Cancer
  NCT07376538 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
  NCT06457906 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
  NCT06197581 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H)
  NCT06146946 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 8 locations
• Short-term and Long-term Outcomes of Colorectal Cancer Treated With Natural Orifice Specimen Extraction Surgery : a National Registry-based Study
  NCT06350370 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma
  NCT07692152 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy
  NCT06667622 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer
  NCT07156045 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• Study on the No.253 Lymph Node Metastasis Patterns in Left-Sided Colon and Rectal Cancer
  NCT06135571 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: All (male and female) · 4 locations
• Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC
  NCT07120282 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
  NCT07203729 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
  NCT07249879 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients
  NCT05762900 · Phase: Phase 2 · Ages: 35 Years and older · Sex: Female · 1 location
• Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer
  NCT06904677 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Common questions

How many trials is Cancer Institute and Hospital, Chinese Academy of Medical Sciences recruiting for?

Cancer Institute and Hospital, Chinese Academy of Medical Sciences is the lead sponsor of 44 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.